NMP and NEP
These substances were identified for action under the Chemicals Management Plan (CMP).
| CAS RN | Common name (abbreviation) |
DSL name | Public comments on the first draft screening assessment | Updated draft assessment | Risk management scope | Proposed conclusion on section 64 criteria | Follow-up activities |
|---|---|---|---|---|---|---|---|
| 872-50-4 | N-Methylpyrrolidone (NMP) | 2-Pyrrolidinone, 1-methyl | HTML | HTML | HTML | Meets one or more of the criteria | Refer to risk management scope |
| 2687-91-4 | N-Ethylpyrrolidone (NEP) | 2-Pyrrolidinone, 1-ethyl | None | Does not meet | Under consideration |
| Date | Activity |
|---|---|
| August 29, 2026 | Publication in Canada Gazette, Part I, of a notice under section 71 of the Canadian Environmental Protection Act (CEPA). |
| January 27, 2024 | Publication and start of a 60-day public comment period on the Updated Draft Screening Assessment for NMP and NEP (including follow-up activities for NEP) and the Risk Management Scope for 2-pyrrolidinone, 1-methyl- (NMP). The related notice was published in the Canada Gazette, Part I: Vol. 158, No. 4. |
| February 4, 2017 | Publication and start of 60-day public comment period on the first draft screening assessment (including follow-up activities). The related notice was published in the Canada Gazette, Part I: Vol. 151, No. 5. |
Information gathering
Section 71 CMP 2026 – Phase 2
In August 2026, a notice was published in the Canada Gazette, Part I: Vol. 160, No. 35 – August 29, 2026, under section 71 of CEPA. This notice applies to NMP (CAS RN 872-50-4). More information is available on the information gathering with respect to certain substances under the CMP web page.
Background
A draft screening assessment for NMP and NEP was published in February 2017. Since then, new information became available regarding exposure to products available to consumers containing NMP and NEP that had the potential to alter assessment conclusions. As a result, the draft screening assessment was updated.